
Pharmaceuticals Biotechnology & THE LAW

Trevor Cook
Catherine Doyle
David Jabbari
of BIRD & BIRD

M
stockton
press

Contents

Acknowledgements xxiii

PART 1 DEVELOPING AND PROTECTING TECHNOLOGY 1

1 INTRODUCTION 3

1.1 The Approach of this Book 3

1.1.1 Scope 3

1.1.2 Structure 4

1.1.3 Pharmaceuticals 4

1.2 Biotechnology 5

1.2.1 Biotechnology and Its Applications 5

1.2.2 Classification of Biotechnological Processes 6

1.2.3 Biotechnology As a Technique for Developing New Drugs 7

1.3 The Industry 7

1.3.1 Overview 7

1.3.2 Pharmaceutical Industry 8

1.3.3 Manufacturers 9

1.3.4 Others 9

1.3.5 Trade Associations 10

1.4 The Legal Framework 11

1.4.1 The Law in England and Wales 11

1.4.2 The English Court System 12

1.4.3 The Regulatory Framework 13

1.5 The European Community 14

1.5.1 Structure and Organisation 14

1.5.2 EC Legislation 14

1.5.3 The Single European Market 15

1.5.4 The Impact of Community Law on Pharmaceuticals and Biotechnology 16

2 REGULATION ON RESEARCH AND DEVELOPMENT 17

2.1 The Scope of Regulatory Control 17

2.1.1 Introduction 17

2.1.2 Planning and Environmental Control 18

2.2 Health and Safety at Work 19

2.2.1 Introduction 19

2.2.2 Dangerous Substances at Work—COSHH 20

2.2.3 The Scope of COSHH 21

2.2.4 The Structure of COSHH 21

2.2.5 New Substances 23

2.3 Control on Laboratory Practice 24

2.3.1 Good Laboratory Practice 24

2.4 Control on Biotechnology 25

2.4.1 Background 25

2.4.2 Problems Associated with the Deliberate Release of Genetically Engineered Organisms 25

2.4.3 Controls on Contained Use and Deliberate Release 27

2.4.4 The Genetic Manipulation Regulations 1989 28

2.4.5 Notification Procedures under the 1989 Regulations 29

2.4.6 Regulatory Control of Planned Release 29

2.4.7 UK Regulation on Planned Release 31

2.4.8 The Environmental Protection Act 1990 32

2.4.9 Enforcement and Offences under the 1990 Act 32

2.4.10 The Worker Safety Directive 33

2.4.11 Other Controls 34

2.5 Controls on Animal Experimentation 34

2.5.1 Background 34

2.5.2 History of UK and EC Regulation 35

2.5.3 The Animals (Scientific Procedures) Act 1986 36

2.5.4 Licences under the 1986 Act 37

2.5.5 Other Provisions of the 1986 Act 37

3 PATENTS AND OTHER INTELLECTUAL PROPERTY 40

3.1 Introduction 40

3.1.1 What is Intellectual Property? 40

3.1.2 What is Sought to be Protected? 41

3.1.3 Types of Intellectual Property 42

3.2 Patents 42

3.2.1 What are Patents? 42

3.2.2 What Value are Patents? 42

3.3 Patenting Procedure 44

3.3.1 Applying for a Patent 44

3.3.2 Prior Art and Examination 45

3.4 Invalidity 46

- 3.4.1 Grounds of Invalidity 46
- 3.4.2 Anticipation and Obviousness 47
- 3.4.3 Width of Claim 48
- 3.4.4 Enablement and Sufficiency 49
- 3.4.5 Amendment and Reissue 50

3.5 Priority Dates 50

- 3.5.1 The Problem 50
- 3.5.2 Grace Periods 51
- 3.5.3 Convention Filings 51
- 3.5.4 First to File v. First to Invent 52
- 3.5.5 Concurrent Conflicting Applications 53

3.6 Claims and Their Interpretation 53

- 3.6.1 The Purpose of the Claims 53
- 3.6.2 Cascading Claims 54
- 3.6.3 Categories of Claim 54
- 3.6.4 Two-part Claims 55
- 3.6.5 Interpreting Claims 55
- 3.6.6 Non-literal Claim Construction 56
- 3.6.7 The Doctrine of Equivalents in the USA 58

3.7 International Aspects of Patents 59

- 3.7.1 Patents Only Apply in One Country 59
- 3.7.2 International Patenting Routes 59
- 3.7.3 European and Community Patent Convention 60

3.8 Other Intellectual Property Rights 61

- 3.8.1 Confidential Information 61
- 3.8.2 Confidential Information and Pharmaceuticals and Biotechnology 62
- 3.8.3 Confidential Information under Different Legal Systems 64
- 3.8.4 Copyright 65
- 3.8.5 Copyright and Genetic Sequences 65
- 3.8.6 Protecting Data 66
- 3.8.7 Plant Breeders' Rights 67
- 3.8.8 Trade Marks 68
- 3.8.9 Regulatory Exclusivity 69

4 PATENTS FOR CHEMICALS 71

4.1 Introduction 71

- 4.1.1 Relevance to Pharmaceuticals 71
- 4.1.2 What is Special about Chemical Patents? 71

4.2 Claims In Chemical Patents 72

4.2.1 Introduction 72

4.2.2 Product and Process Claims and Exclusions from Patentability 72

4.2.3 Claims to Chemical Entities 73

4.2.4 The Scope of Chemical Claims 74

4.2.5 Method and Composition Claims 75

4.2.6 Product-by-process Claims 76

4.2.7 Use Claims 76

4.3 Chemical Patent Issues 77

4.3.1 Anticipation and Obviousness 77

4.3.2 Conflicting Applications 77

4.3.3 Enablement 78

4.3.4 Prediction and Scope 80

4.3.5 Selection Inventions 82

4.3.6 Optical Isomers 84

4.3.7 Case Study: Cimetidine 86

4.3.8 Case Study: Ranitidine 89

4.3.9 Patenting Strategy for NCEs 90

5 PATENTS AND RELATED ISSUES SPECIFIC TO PHARMACEUTICALS AND MEDICAL DEVICES 92

5.1 Introduction 92

5.1.1 Issues in Pharmaceuticals and Patents 92

5.2 Limitations on Patentability and the Responses to This 92

5.2.1 Exclusions from Patentability in Certain Jurisdictions 92

5.2.2 Medical Use Exclusions for Patentability 93

5.2.3 What is Medical Treatment? 94

5.2.4 First Medical Use 94

5.2.5 Second and Subsequent Medical Uses 95

5.2.6 Formulation Claims 97

5.2.7 Claims for AZT 97

5.2.8 Borderline Medical Uses 98

5.2.9 Patents for Pharmaceutical Packs 99

5.3 Extending Protection for Pharmaceuticals 100

5.3.1 Development of the Law in the UK 100

5.3.2 Repeal of Licence of Right Provisions 101

5.3.3 Data Exclusivity 102

5.3.4 History of the Data Exclusivity Provisions 103

5.3.5 The Period of Data Exclusivity 104

5.3.6 Position on Data Exclusivity in the UK and Other Member States 105

5.3.7 Confidential Information and Data Exclusivity 106

5.3.8 Patent Term Restoration 107

5.3.9	Specifics of the SPC Proposal	108
5.3.10	Prospects for the SPC Proposal	109
6	PATENTS AND BIOTECHNOLOGY	111
6.1	Introduction	111
6.1.1	Patent Concerns of the Biotechnology Sector	111
6.1.2	Genetic Engineering	111
6.1.3	Monoclonal Antibody Technology	114
6.1.4	Patent Issues with Monoclonal Antibodies	114
6.2	Limits on Patentable Subject Matter	115
6.2.1	Introduction	115
6.2.2	The European Patent Convention	116
6.2.3	The Approach of the EPO	118
6.2.4	Comparison with the USA	120
6.3	The Extent of Protection Available	121
6.3.1	Introduction	121
6.3.2	Patent Claims in Biotechnology	122
6.3.3	The Product of Nature Problem	123
6.3.4	The t-PA Case	125
6.4	Adequacy of Description and Deposit Requirements	129
6.4.1	General Principles	129
6.4.2	Deposit Requirements	130
6.4.3	Deposit Provisions in the UK and under the EPC	131
6.5	Future Developments	134
6.5.1	The Draft EC Directive	134
6.5.2	Other Developments	135
6.5.3	Lessons to be Learnt	136
7	AGREEMENTS FOR DEVELOPING TECHNOLOGY	138
7.1	Preliminary Issues	138
7.1.1	Introduction	138
7.1.2	Structures	138
7.2	Ownership of IPRs	139
7.2.1	Who Owns the Technology?	139
7.2.2	Foreground and Background	141
7.2.3	Participation in R&D by Academics	143
7.3	Competition Law Issues	145
7.3.1	Article 85	145

7.3.2	Notification	146
7.3.3	Block Exemptions	147
7.3.4	The Structure of Block Exemptions	147
7.4	Subcontracting Arrangements	148
7.4.1	Commissioned Development Agreements	148
7.4.2	Agreements for Conducting Clinical Trials	149
7.5	Collaborative Research and Development	150
7.5.1	Structure and Purpose	150
7.5.2	Government-sponsored R&D Collaboration	151
7.5.3	Competition Law and Collaborative Research and Development	151
7.5.4	Notice on Co-operation Agreements	153
7.5.5	Research and Development Block Exemption	153
7.5.6	Specialisation Agreements Block Exemption	154
7.6	Technical Goal of the Collaboration	155
7.6.1	The Work Programme	155
7.6.2	Key Personnel	155
7.6.3	Identification and Disclosure of Background	156
7.6.4	Other Aspects of Achieving the Technical Goal	156
7.7	Marketing Objective of the Collaboration	157
7.7.1	The Importance of Identifying the Marketing Objective	157
7.7.2	Protection and Ownership of the Results	157
7.7.3	Sharing the Benefits of the Results	159
7.7.4	Allocation of Production	159
7.7.5	Collaboration between the Parties by Way of Assignment or Licensing of the Results of the Project to Third Parties	160
7.7.6	Cross-licences between Each Collaborator to the Other under the Results of the Project and any Pre-existing Technology	160
7.8	Exit Routes from the Collaboration	162
7.8.1	Rights to Terminate	162
7.8.2	Rights of Withdrawal/Ejection from the Project	163
PART 2	PROVING TECHNOLOGY	165
8	LEGAL AND ETHICAL ISSUES IN CLINICAL TESTING	167
8.1	Background	167
8.1.1	Introduction	167
8.1.2	Guidelines in the UK	167
8.1.3	Phase I Tests	168
8.1.4	Phase II Tests	169

8.1.5	Phase III Tests	170
8.1.6	Phase IV Tests	171
8.2	Regulatory Controls on Clinical Trials	171
8.2.1	Extent of EC Involvement	171
8.2.2	Clinical Trials Certificate	172
8.2.3	Standard Conditions for CTCs	172
8.2.4	Clinical Trial Exemption	173
8.2.5	Doctors and Clinical Trials	174
8.3	Ethical Aspects of Clinical Trials	175
8.3.1	The Role of Ethics Committees	175
8.3.2	Payments to Investigators and Links with Sponsors	176
8.3.3	Liability of Ethics Committees	177
8.4	Research In Patients	177
8.4.1	Introduction	177
8.4.2	Therapeutic and Non-therapeutic Research	178
8.4.3	Therapeutic Research	179
8.4.4	Risk/Benefit Analysis	179
8.5	Consent	180
8.5.1	Introduction	180
8.5.2	Consent and Research on Patients	182
8.5.3	Consent and Research on Volunteers	183
8.5.4	Children	183
8.6	Other Aspects	184
8.6.1	Confidentiality	184
8.6.2	Access to Records	185
8.6.3	Compensation	186
9	REGULATION ON THE LICENSING OF MEDICINAL PRODUCTS	188
9.1	In the European Community	188
9.1.1	Introduction	188
9.1.2	Medicinal Products	189
9.1.3	History of EC Measures to Date	189
9.1.4	Implementation of Medicinal Products Directives	192
9.1.5	Proposals for Further EC Measures	193
9.1.6	The Harmonisation Activity of the EC Commission	193
9.1.7	National Licensing Delays	194
9.1.8	Mutual Recognition and Other Measures	195
9.1.9	The Original Multistate Procedure	195
9.1.10	The Revised Multistate Procedure	196

9.1.11	The Mechanics of a Multistate Application	197
9.1.12	Evaluation of the New Multistate Procedure	198
9.1.13	Concertation Procedure for High Technology Medicinal Products	198
9.1.14	Mechanics of the Concertation Procedure	199
9.1.15	Evaluation of the Concertation Procedure	199
9.2	UK Regulation	199
9.2.1	The Interrelation of the UK and EC Law in Relation to Regulation	199
9.2.2	The Medicines Act 1968	200
9.2.3	Background to the Medicines Act 1968	200
9.2.4	The Medicines Commission and the Committee on the Safety of Medicines	201
9.2.5	The Licensing System in the UK	202
9.2.6	Product Licences	202
9.2.7	Applications for Product Licences	203
9.2.8	Safety Quality and Efficacy	204
9.2.9	The Meaning of 'Medicinal Products'	205
9.2.10	Items Excluded from the Definition of Medicinal Products	206
9.2.11	Exclusions from the Scope of Medicines Act Control	206
9.3	Proposals for the Future	206
9.3.1	The Background to the Proposals for Future Regulation	206
9.3.2	Proposals for the Future Regulation of Medicines	207
PART 3 COMMERCIALISING TECHNOLOGY		209
10 POST INITIAL APPROVAL REGULATION OF MEDICINAL PRODUCTS		211
10.1	Introduction	211
10.1.1	Background	211
10.2	Monitoring	212
10.2.1	Standard Provisions for Product Licences	212
10.2.2	Postmarketing Surveillance	214
10.2.3	Suspension and Revocation of Authorisation	214
10.3	Further Approvals	215
10.3.1	Introduction	215
10.3.2	Abridged Applications	216
10.3.3	Essential Similarity	216
10.3.4	Combinations	217
10.3.5	Parallel Importation	218
10.3.6	Attempts by Innovators to Impede the Grant of Further Product Licences	218
10.4	Manufacture and Patterns of Trade in Medicinal Products	219
10.4.1	Introduction	219

10.4.2	Manufacturers' Licences	219
10.4.3	Good Manufacturing Practice	220
10.4.4	Wholesale Dealers' Licences	221
10.4.5	Outlets for Medicinal Products	222
10.4.6	Controls on Labelling and Packaging Inserts	223
10.5	Advertising and Promotion	224
10.5.1	Introduction	224
10.5.2	The Medicines Act Controls	224
10.5.3	Other Statutory Controls on Advertising	225
10.5.4	Self-regulatory Codes	226
10.5.5	The Proposed Council Directive on Advertising Medicinal Products	228
10.6	Pharmaceutical Pricing	229
10.6.1	Introduction	229
10.6.2	The Common External Tariff	229
10.6.3	European Approaches to Price Control	230
10.6.4	The UK Pharmaceutical Price Regulation Scheme	231
10.6.5	The Working of the PPRS	232
10.6.6	Indicative Prescribing and Negative Lists	232
10.6.7	Parallel Importing	233
10.6.8	Discrimination through Pricing	233
10.6.9	The Approach of the Commission and the European Court of Justice	234
10.6.10	Evaluating Pharmaceutical Price Levels	235
10.6.11	The Problem of National Production Costs	235
10.6.12	The Consumer Viewpoint	236
10.6.13	The Role of Consumer Expenditure	237
10.6.14	Conclusion	237
10.6.15	Proposals for the Future	238
10.6.16	Consensual Price Controls	238
11	REGULATION IN AREAS OTHER THAN, BUT RELATED TO, MEDICINAL PRODUCTS	239
11.1	Introduction	239
11.1.1	The Scope of Control on Medicinal Products	239
11.1.2	Borderline Cases	239
11.2	Food	241
11.2.1	Scope of Control	241
11.2.2	The Mechanism of Control	242
11.2.3	Novel Foods	242
11.2.4	Vitamins and Dietary Supplements	242
11.2.5	Overlap with Medicines Act	244
11.3	Cosmetics	245
11.3.1	Scope of Control	245

11.3.2	Mechanism of Control	246
11.3.3	Overlap with Pharmaceuticals	246
11.3.4	Part II of the Consumer Protection Act 1987	247
11.3.5	Other Controls	247
11.4	Medical Devices	248
11.4.1	Introduction	248
11.4.2	Control under the Medicines Act 1968	248
11.4.3	DH Voluntary Registration Scheme	249
11.4.4	The Drug Tariff	249
11.4.5	Developments in the EC	250
11.5	Veterinary Medicinal Products, Hormones and Animal Foodstuffs	251
11.5.1	Introduction	251
11.5.2	Animal Foodstuffs	251
11.5.3	Hormones	252
11.5.4	Veterinary Medicinal Products	252
11.5.5	Scope of Regulation	253
11.5.6	UK Control	254
12	TRADE MARKS AND PHARMACEUTICALS	255
12.1	General Principles	255
12.1.1	The Value of Trade Marks	255
12.1.2	What is a Trade Mark?	255
12.1.3	Registration	256
12.1.4	Registrability	257
12.1.5	Unregistered Trade Marks, Passing off and Unfair Competition	259
12.1.6	The Benefits of Registration of Trade Marks in Relation to Infringement	259
12.1.7	Registration Practice	260
12.1.8	Licensing and Assignment	261
12.1.9	Proper Use of Trade Marks	261
12.2	Pharmaceuticals and Trade Marks	263
12.2.1	Introduction	263
12.2.2	Non-proprietary Names	264
12.2.3	Choice of Pharmaceutical Trade Marks	266
12.2.4	More Stringent Test for Registering Pharmaceutical Brand Names as Trade Marks	267
12.2.5	Protection for Shapes and Colours	268
12.2.6	Public Policy Considerations	270
12.2.7	Comparative and Referential Advertising	271
12.3	International Aspects	272
12.3.1	International Registration Procedures	272

12.3.2	Harmonisation of EC Trade Mark Law	273
12.3.3	Competition Law and Trade Marks	275
13	AGREEMENTS FOR EXPLOITING TECHNOLOGY	277
13.1	General Considerations	277
13.1.1	Structures	277
13.2	Licensing	278
13.2.1	Reasons for Granting a Licence	278
13.2.2	Reasons for Taking a Licence	280
13.2.3	Structuring the Licence Agreement	281
13.2.4	Licensing Policy and Approach	281
13.3	Preliminary Agreements	283
13.3.1	Purpose	283
13.3.2	Confidentiality and Material Transfer Agreements	283
13.3.3	Heads of Agreement and Letters of Intent	284
13.3.4	Options and Rights of First Refusal	284
13.4	Licensing Terms	285
13.4.1	Identification of the Licensed IPRs	285
13.4.2	Limitations upon the Rights Granted	286
13.4.3	Types of Licence to be Granted	287
13.4.4	Structuring Payments for the Rights Granted	289
13.4.5	Royalty Rates	292
13.4.6	Improvements	295
13.4.7	Confidentiality	295
13.4.8	Technical Assistance and Training	296
13.4.9	Quality Control	296
13.4.10	Term, Termination and Post-termination	297
13.4.11	Warranties and Protection from Infringement Claims from Third Parties	298
13.4.12	Most Favoured Nation Clause	299
13.4.13	Licensee's Protection against Unlicensed Competition	299
13.4.14	Other Provisions	300
13.4.15	Conclusion	301
13.5	Competition Law Constraints on Licence Agreements	302
13.5.1	Background	302
13.5.2	Domestic Law Constraints on Licensing	302
13.5.3	Patent Licensing Block Exemption	303
13.5.4	Know-how Licensing Block Exemption	303
13.5.5	Comparison Between the Block Exemptions on Patent and Know-how Licensing	304

13.6 Distribution: Co-promotion and Co-marketing 305

13.6.1 Background 305

13.6.2 Co-promotion 306

13.6.3 Co-marketing 309

13.7 Competition Law and Distribution Arrangements 310

13.7.1 Introduction 310

13.7.2 Exclusive Distribution Block Exemption 310

13.7.3 Exclusive Purchasing Block Exemption 311

13.7.4 Comparison between Exclusive Distribution and Purchasing Block Exemptions 311

PART 4 DEFENDING TECHNOLOGY 313

14 CONTROL OF COMPETING ACTIVITIES 315

14.1 Introduction 315

14.1.1 This and the Following Chapters 315

14.1.2 What Constitutes Infringing Activity? 315

14.2 Patent Infringement 316

14.2.1 Under the 1977 Act 316

14.2.2 The 'Saccharin' Doctrine and the New Law 317

14.2.3 Proving Infringement of Process Patents 318

14.2.4 Foreign Suppliers and Patent Infringement 319

14.3 Special Defences to Patent Infringement 320

14.3.1 Introduction 320

14.3.2 Exemptions for Non-commercial Acts and for Experimental Use 320

14.3.3 Compulsory Licences 322

14.3.4 Crown Use 323

14.4 Competition Law Defences of General Application to IPRs 323

14.4.1 Parallel Importation 323

14.4.2 EC Defences 324

14.4.3 Application in Practice 325

14.4.4 Limitations on the Exhaustion Principle 326

14.4.5 Application of the Exhaustion Principle to Trade Marks 327

14.4.6 The Doctrine of Common Origin 327

14.4.7 Repackaging 328

14.4.8 Other Eurodefences 329

14.4.9 Use Other than in Relation to IPRs 331

14.5 Stopping Infringement 331

14.5.1 The Position in the United Kingdom 331

14.5.2 Patent Actions 333

14.5.3 Trade Mark and Passing off Actions	333
14.5.4 Confidential Information and Copyright Actions	334
14.6 Interlocutory Injunctions	335
14.6.1 Introduction	335
14.6.2 Arguments Advanced in Applications for Interlocutory Injunctions	336
14.6.3 Special Factors and Interlocutory Injunctions	337
14.6.4 Special Interlocutory Injunctions	338
14.6.5 Obtaining Information about Infringement	339
14.6.6 Consequences of an Interlocutory Injunction	339
14.7 Patents Court Procedure	340
14.7.1 Starting the Action	340
14.7.2 Admissions, Discovery and Notices of Experiments	342
14.7.3 Directions for Trial	342
14.7.4 The Trial, Judgement and Appeal	343
14.7.5 Patents County Court	344
14.7.6 Interaction with Patent Office Jurisdictions	345
14.7.7 Patent Litigation in Other Countries	346
14.8 Remedies for Infringement	347
14.8.1 The Consequences of the Judgement	347
14.8.2 Damages	347
14.8.3 Legal Costs	348
14.8.4 Delivery up	349
15 PRODUCT LIABILITY	351
15.1 Introduction	351
15.1.1 Background	351
15.1.2 Claims in Contract	352
15.1.3 Claims in Negligence	353
15.2 Strict Liability	355
15.2.1 EC Product Liability Directive	355
15.2.2 The Consumer Protection Act 1987	355
15.2.3 The Scope of the 1987 Act	356
15.2.4 Defects under the 1987 Act	356
15.2.5 Patient Information	357
15.2.6 Who is Liable under the 1987 Act?	358
15.2.7 Defences Available under the 1987 Act	358
15.2.8 The Issue of Causation	359
15.2.9 Responses	360
15.2.10 The New EC General Product Safety Directive	361

15.3 How Long Does Liability Last? 362

15.3.1 The General Principle 362

15.3.2 Limitation and Negligence 362

15.3.3 Limitation and the Consumer Protection Act 1987 363

15.4 Types of Pharmaceutical Product Defect 363

15.4.1 Introduction 363

15.4.2 Manufacturing Defects 363

15.4.3 Packaging Defects 364

15.4.4 Design Defects 364

15.4.5 The Development Risks Defence 366

15.4.6 Marketing Defects 368

15.5 The Position of Doctors and Pharmacists in Drug Claims 370

15.5.1 Negligent Prescribing or Supply 370

15.5.2 The *Prendergast* Case 371

15.5.3 The *Dwyer* Case 372

15.5.4 Prescribing and Informed Consent 373

15.6 Procedural Aspects of Drug Injury Litigation in the UK 373

15.6.1 Introduction 373

15.6.2 Jurisdiction 373

15.6.3 Before the Litigation Begins—the Pre-action Discovery 374

15.6.4 The Litigation Begins 374

15.6.5 The Pleadings 375

15.6.6 Interim Payment of Damages 376

15.6.7 Directions for Trial 376

15.6.8 Discovery and Inspection of Documents 377

15.6.9 Preparation of Evidence and Documents for Trial 378

15.6.10 The Trial, Judgement and Appeal 378

15.6.11 Damages 379

15.6.12 Costs and Settlement 380

15.7 Class Actions 381

15.7.1 Introduction 381

15.7.2 Problems Faced by Class Actions 383

16 THE LAW AND THE REGULATORY FRAMEWORK 385

16.1 Introduction 385

16.1.1 Interrelation of Law and Regulation 385

16.2 Review and Appeal under the Medicines Act 1968 385

16.2.1 Applications for Licences and Certificates: Committee Procedures 385

16.2.2 Considerations by Committee 386

16.2.3 Representations to and Hearings before the Committee 387

16.2.4	Representations to and Hearings before the Medicines Commission	388
16.2.5	Hearings by 'a Person Appointed'	388
16.2.6	Enforcement of the Medicines Act under the Criminal Law	389
16.2.7	Medicines Act Appeal Procedure	390

16.3 Judicial Review 391

16.3.1	Introduction	391
16.3.2	Substantive Law of Judicial Review	392
16.3.3	Standing	394
16.3.4	Procedural Aspects of Judicial Review	394

16.4 Application to Medicines Act 1968 395

16.4.1	Challenging Decisions under the Medicines Act 1968	395
16.4.2	Judicial Review Versus Statutory Review	396
16.4.3	Third Party Challenges	398

16.5 Application to Other Areas 401

16.5.1	Other Bodies in the Pharmaceutical Industry	401
16.5.2	Use of Judicial Review by Third Parties in Other Areas	401
16.5.3	Prospects for the Future	402

APPENDICES 405

Experimentation, Including Genetic Manipulation	407
1 86/609/EEC—Council Directive on the approximation of laws, regulations and administrative provisions of Member States regarding the protection of animals used for experimental and other purposes [excluding Annex II, tables & figures]	409
2 87/18/EEC—Council Directive on the harmonisation of laws, regulations and administrative provisions relating to the application of the principles of good laboratory practice and the verification of their applications for tests on chemical substances	420
3 88/320/EEC—Council Directive on the inspection and verification of Good Laboratory Practice (GLP) [excluding Annex]	424
4 90/219/EEC—Council Directive on the contained use of genetically modified micro-organisms	429
5 90/220/EEC—Council Directive on the deliberate release into the environment of genetically modified organisms	448
6 90/679/EEC—Council Directive on the protection of workers from risks related to exposure to biological agents at work	470
7*The Genetic Manipulation Regulations 1989 (SI 1989/1810)	488

8*Environmental Protection Act 1990 Part VI	496
Intellectual Property	519
9 COM(90)101 final—SYN 255—Proposal for a Council Regulation concerning the creation of a supplementary protection certificate for medicinal products	521
10 COM(88)496 final—Proposal for a Council Directive on the legal protection of biotechnological inventions	527
11 65/65/EEC—Council Directive on the approximation of the provisions laid down by law, regulation or administrative action relating to proprietary medicinal products [Incorporating amendments introduced by 75/319/EEC, 83/570/EEC, 87/21/EEC]	538
12 75/318/EEC—Council Directive on the approximation of the laws of Member States relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of proprietary medicinal products [Incorporating amendments introduced by 83/570/EEC, 87/19/EEC]	548
13 75/319/EEC—Second Council Directive on the approximation of the provisions laid down by law, regulation or administrative action relating to proprietary medicinal products [Incorporating amendments introduced by 78/420/EEC, 83/570/EEC]	572
14 82/C115/05—Commission communication on parallel imports of proprietary medicinal products for which marketing authorisations have already been granted (<i>Official Journal of the European Communities</i> No. C 115/5 of 6.5.1982)	589
15 86/C310/08—Commission communication on the compatibility with Article 30 of the EEC treaty of measures taken by Member States relating to price controls and reimbursement of medicinal products (<i>Official Journal of the European Communities</i> No. C 310 of 4.12.1986)	595
16 87/22/EEC—Council Directive on the approximation of national measures relating to the placing on the market of high-technology medicinal products, particularly those derived from biotechnology	604
17 89/105/EEC—Council Directive relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion within the scope of national health insurance systems	610
18 89/341/EEC—Council Directive amending Directives 65/65/EEC, 75/318/EEC and 75/319/EEC on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products	618

19	89/342/EEC—Council Directive extending the scope of Directives 65/65/EEC and 75/319/EEC and laying down additional provisions for immunological medicinal products consisting of vaccines, toxins or serums and allergens	624
20	89/343/EEC—Council Directive extending the scope of Directives 65/65/EEC and 75/319/EEC and laying down additional provisions for radiopharmaceuticals	628
21	89/381/EEC—Council Directive extending the scope of Directives 65/65/EEC and 75/319/EEC and laying down additional provisions for medicinal products derived from human blood or human plasma	633
22	COM(89)607 final—SYN 229—Proposal for a Council Directive on the wholesale distribution of medicinal products for human use	638
23	COM(89)607 final—SYN 230—Proposal for a Council Directive concerning the legal status for the supply of medicinal products for human use	643
24	COM(89)607 final—SYN 231—Proposal for a Council Directive on the labelling of medicinal products for human use and on package leaflets	647
25	COM(90)212 final—SYN 273—Proposal for a Council Directive on advertising of medicinal products for human use	655
26	COM(90)283 final—SYN 309—Proposal for a Council Regulation (EEC) laying down Community Procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products	663
27	COM(90)283 final—SYN 310—Proposal for a Council Directive amending Directives 65/65/EEC, 75/318/EEC and 75/319/EEC in respect of medicinal products	694
	Agreements	707
28	Notice concerning agreements, decisions and concerted practices in the field of cooperation between enterprises (<i>Official Journal of the European Communities</i> No. C 75 29.7.1968, p.3)	709
29	Commission Notice concerning its assessment of certain subcontracting agreements in relation to Article 85(1) of the EEC Treaty (<i>Official Journal of the European Communities</i> No. C1, 3.1.1979, p.2)	715
30	1983/83—Commission Regulation on the application of Article 85(3) of the Treaty to categories of exclusive distribution agreements	718
31	1983/84—Commission Regulation on the application of Article 85(3) of the Treaty to categories of exclusive purchasing agreements	725

32	84/C101/02—Commission Notice concerning Commission Regulations (EEC) No. 1983/83 and No. 1984/83 on the application of Article 85(3) of the Treaty to categories of exclusive distribution and exclusive purchasing agreements	734
33	418/85—Commission Regulation on the application of Article 85(3) of the Treaty to categories of research and development agreements	743
34	2349/84—Commission Regulation on the application of Article 85(3) of the Treaty to certain categories of patent licensing agreements	755
35	556/89—Commission Regulation on the application of Article 85(3) of the Treaty to certain categories of know-how licensing agreements	769
	Product Safety	789
36	85/374/EEC—Council Directive on the approximation of the laws, regulations and administrative provisions of the Member States concerning liability for defective products	791
37	COM(90)259 final—SYN 192—Amended proposal for a Council Directive concerning general product safety	800
38	Glossary	813
	Suggestions for further reading	816
	Case Table	817
	Legislation Table	824
	Index	830